Table 1 |
|||||
|
Demographic features of study groups |
|||||
|
Group |
Age (yrs) |
ANA (EU) |
Female (%) |
AA (%) |
Hispanic (%) |
|
|
|||||
|
HC High ANA (n = 18) |
33.8 ± 3.4* |
78.4 ± 10.0* |
83 |
22 |
6 |
|
HC Low ANA (n = 16) |
43.1 ± 3.7 |
7.0 ± 0.6 |
75 |
25 |
0 |
|
SLE (n = 14) |
38.0 ± 4.0 |
182.4 ± 15.4 |
93 |
43 |
7 |
|
P** |
0.2 |
0.001# |
0.4 |
0.4 |
0.6 |
|
|
|||||
|
*Values represent mean and standard error of the mean. **P-values were calculated by one-way ANOVA or Fisher's exact test. # Mean ANA in SLE was significantly higher than in the High ANA HC group (P <0.05). ANA, antinuclear antibodies; SLE, systemic lupus erythematosus. |
|||||
|
Li et al. Arthritis Research & Therapy 2011 13:R38 doi:10.1186/ar3271 |
|||||